FDA decision on Opdivo/Yervoy in liver cancer due next MarchThe FDA has started a priority review of Bristol-Myers Squibb’s immuno-oncology combination of Opdivo and Yervoy in liver Share XFDA decision on Opdivo/Yervoy in liver cancer due next Marchhttps://pharmaphorum.com/news/fda-decision-on-opdivo-yervoy-in-liver-cancer-due-next-march/
Labour peer says he opposes Corbyn-style state-funded drugs firmA Labour peer has spoken out against the idea of a nationalised drugs industry, saying that proposals for Share XLabour peer says he opposes Corbyn-style state-funded drugs firmhttps://pharmaphorum.com/news/labour-peer-corbyn-state-funded-drugs/
Celgene scores FDA okay for thalassaemia drug ReblozylThe FDA has approved Celgene and Acceleron’s Reblozyl, which is the first drug to be approved in the Share XCelgene scores FDA okay for thalassaemia drug Reblozylhttps://pharmaphorum.com/news/celgene-scores-fda-okay-for-thalassaemia-drug-reblozyl/
NICE backs NHS funding for two cannabis-based drugs for first timeNICE has recommended two of GW Pharma’s cannabis-based medicines, the first time that medicines derived from the plant Share XNICE backs NHS funding for two cannabis-based drugs for first timehttps://pharmaphorum.com/news/nice-includes-bayer-gws-cannabis-based-sativex-in-ms-guideline-for-first-time/
First Rituxan biosimilar Truxima set to make its debut in USBiosimilar competition to Roche’s big-selling Rituxan has arrived in the US, with Teva gearing up to launch its Share XFirst Rituxan biosimilar Truxima set to make its debut in UShttps://pharmaphorum.com/news/first-rituxan-biosimilar-truxima-set-to-makes-its-debut-in-us/
Corbyn accuses Tories of planning deal to hike drug prices with Trump as election loomsDrug prices have become an issue in the UK’s general election, after Labour leader Jeremy Corbyn accused the Share XCorbyn accuses Tories of planning deal to hike drug prices with Trump as election loomshttps://pharmaphorum.com/news/corbyn-accuses-tories-of-planning-deal-to-hike-drug-prices-with-trump-as-election-looms/
Stephen Hahn nominated as next FDA CommissionerStephen Hahn has been formally nominated by President Trump as the next FDA Commissioner, as acting chief Ned Share XStephen Hahn nominated as next FDA Commissionerhttps://pharmaphorum.com/news/stephen-hahn-nominated-as-next-fda-commissioner/
Amgen pays $2.7bn to harness BeiGene’s China marketing muscleFuelled by sweeping regulatory reforms and a massive ageing population, China is a key market for most big Share XAmgen pays $2.7bn to harness BeiGene’s China marketing musclehttps://pharmaphorum.com/news/amgen-pays-2-7bn-to-harness-beigenes-china-marketing-muscle/
Novartis’ Cosentyx didn’t EXCEED Humira in psoriatic arthritisBeating AbbVie’s TNF blocker Humira in a head-to-head trial has become a rite of passage for new interleukin-targeting Share XNovartis’ Cosentyx didn’t EXCEED Humira in psoriatic arthritishttps://pharmaphorum.com/news/novartis-cosentyx-cant-exceed-humira-in-psoriatic-arthritis/
